arrow
V

Vincent K. Lam

Johns Hopkins University School of Medicine
H指数:33
被引数:5,098

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee

不可切除的局部晚期非小细胞肺癌的放射治疗:国际肺癌研究协会(IASLC)高级放射技术(ART)分委会针对挑战性场景的实用多学科方法

2025-11-140
PRE
Discovery of Methylated DNA Biomarkers for Potential Nonendoscopic Detection of Barrett's Esophagus and Esophageal Adenocarcinoma

甲基化DNA生物标志物的发现:用于Barrett's Esophagus和Esophageal Adenocarcinoma潜在的内镜外检测

2025-10-013
PRE
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study

Nivolumab联合治疗晚期胃癌和胃食管交界癌患者: II期胃癌研究

2025-02-010
OAAI
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis

改变EGFR突变的NSCLC患者的治疗和转移性疾病模式: 学术胸科医学研究者的联盟注册分析

2025-01-010
OA
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
2025-01-010
PRE
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

CTLA4阻断消除KEAP1/STK11-related对PD-(L)1抑制剂的抗性

Nature
IF48.5
2024-10-090
OAAI
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC

EGFR突变转移性NSCLC长期存活者的特征

2024-08-012
OA
Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA comprehensive genomic profiling
2024-03-220
PRE
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses

新辅助nivolumab或nivolumab联合LAG-3抑制剂relatlimab治疗可切除食管/胃食管交界处癌: Ib期试验和ctDNA分析

2024-03-1913
OAAI
Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer

接受免疫检查点阻断治疗转移性非小细胞肺癌的长期应答者的临床和基因组特征

2024-03-012
OAAI